Metastasiertes Magenkarzinom: Ist eine Zweitlinien-Chemotherapie sinnvoll?

Zusammenfassung

Für die überwiegende Mehrzahl der Patienten mit Magenkarzinom ist die Therapie palliativ. Eine Vielzahl neuer Substanzen hat nachgewiesene Wirksamkeit beim Magenkarzinom. Eine Erstlinientherapie basierend auf Cisplatin/Fluoropyrimidin +/- Anthrazyklin oder +/- Docetaxel ist international etabliert. Der Einsatz einer Zweitlinientherapie variiert regional deutlich, was die Unsicherheit bezüglich des Nutzens der Therapie widerspiegelt. Beim ASCO 2009 wurde erstmalig eine Studie der deutschen AIO-Studiengruppe vorgestellt, die eine Überlebensverlängerung durch eine Zweitlinientherapie beim Magencarcinom im randomisierten Vergleich von Irinotecan mit Best Supportive Care gezeigt hat. Eine Zweilinientherapie sollte demnach jedem Patienten in gutem Allgemeinzustand und bei bestehendem Therapiewunsch angeboten werden. Phase-II-Daten zeigen Aktivität von Taxanen und Irinotecan als Mono- oder Kombinationstherapie mit Platinderivaten oder Fluoropyrimidinen. Nach Datenlage kann keine Substanz in der Zweilinientherapie einer anderen vorgezogen werden. Die Wahl sollte sich nach der Art der Vortherapie, dem Performance-Status des Patienten, dem Nebenwirkungsprofil und den Kontraindikationen einzelner Substanzen richten. Die Therapie mit biologischen Substanzen wie Everolimus oder Sunitinib wird aktuell in kontrollierten Studien untersucht.

Abstract

For the majority of patients with gastric cancer the aim of treatment is palliative. An increasing number of substances could prove activity in gastric cancer. A first-line regime based on cisplatin/ fluoropyrimidine +/- an anthracycline or +/- docetaxel is internationally accepted. The use of second-line chemotherapy varies dramatically between countries, reflecting the uncertainty of its benefit. At the ASCO conference 2009, the first randomized phase III study for second-line chemotherapy was presented by the German AIO group, which showed a significant prolongation of survival with second-line irinotecan compared to best supportive care. A second-line chemotherapy should therefore be discussed with every patient in good performance status. Phase II data show activity of second-line taxanes and irinotecan as monotherapy or combined with cisplatin or a fluoropyrimidin. The data does not show any regimen superior to another. The choice of second-line chemotherapy should depend on the pre-treatment, the performance status of the patient and contraindications of substances. Studies investigating new agents like everolimus and sunitinib are currently being conducted.

metastasiertes Magenkarzinom - Zweitlinien-Chemotherapie

metastatic gastric cancer - second-line chemotherapy

Literatur

• 1 Assersohn L, Brown G, Cunningham D. et al . Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma.  Ann Oncol. 2004;  15 64-69
• 2 Baek J H, Kim J G, Sohn S K. et al . Biweekly irinotecan and cisplatin as second-line chemotherapy in pretreated patients with advanced gastric cancer.  J Korean Med Sci. 2005;  20 966-970
• 3 Barone C, Basso M, Schinzari G. et al . Docetaxel and oxaliplatin combination in second-line treatment of patients with advanced gastric cancer.  Gastric Cancer. 2007;  10 104-111
• 4 Cascinu S, Graziano F, Cardarelli N. et al . Phase II study of paclitaxel in pretreated advanced gastric cancer.  Anti-cancer Drugs. 1998;  9 307-310
• 5 Catalano V, Graziano F, Santini D. et al . Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?.  Brit J Cancer. 2008;  99 1402-1407
• 6 Chun J H, Kim H K, Lee J S. et al . Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy.  Jap J Clin Oncol. 2004;  34 8-13
• 7 Cunningham D, Allum W H, Stenning S P. et al . Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.  New Engl J Med. 2006;  355 11-20
• 8 Giuliani F, Gebbia V, De Vita F. et al . Docetaxel as salvage therapy in advanced gastric cancer.  Anticancer Res. 2003;  23 4219-4222
• 9 Giuliani F, Molica S, Maiello E. et al . Irinotecan (CPT-11) and mitomycin-C (MMC) as second-line therapy in advanced gastric cancer.  Am J clin Oncol. 2005;  28 581-585
• 10 Graziano F, Catalano V, Baldelli A M. et al . A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer.  Ann Oncol. 2000;  11 1263-1266
• 11 Hamaguchi T, Shirao K, Yamamichi N. et al . A phase II study of sequential methotrexate and 5-fluorouracil chemotherapy in previously treated gastric cancer, JCOG 9207 trial.  Jap J Clin Oncol. 2008;  38 432-437
• 12 Kanat O, Evrensel T, Manavoglu O. et al . Single-agent irinotecan as second-line treatment for advanced gastric cancer.  Tumori. 2003;  89 405-407
• 13 Kim S T, Kang W K, Kang J H. et al . Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer.  Brit J Cancer. 2005;  92 1850-1854
• 14 Kodera Y, Ito S, Mochizuki Y. et al . A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric Cancer (CCOG0302 study).  Anticancer Res. 2007;  27 2667-2671
• 15 Kunisaki C, Imada T, Yamada R. et al . Phase II study of docetaxel plus cisplatin as a second-line combined therapy in patients with advanced gastric carcinoma.  Anticancer Res. 2005;  25 2973-2977
• 16 Lacave A J, Wils J, Diaz-Rubio E. et al . cis-Platinum as second-line chemotherapy in advanced gastric adenocarcinoma.  Eur J Cancer Clin Oncol. 1985;  21 1321-1324
• 17 Lee J L, Ryu M H, Chang H M. et al . A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy.  Cancer Chemother Pharmacol. 2008;  61 631-637
• 18 Lee K W, Kim J H, Yun T. et al . Phase II study of low-dose paclitaxel and cisplatin as a second-line therapy after 5-fluorouracil/platinum chemotherapy in gastric cancer.  Journal of Korean medical science. 2007;  22 Suppl S115-121
• 19 Ohtsu A, Yoshida S, Saito D. et al . An early phase II study of 5-fluorouracil combined with cisplatinum as a second line chemotherapy against metastatic gastric cancer.  Jap J Clin Oncol. 1991;  21 120-124
• 20 Park S H, Kang W K, Lee H R. et al . Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimen.  Am J Clin Oncol. 2004;  27 477-480
• 21 Park S H, Kim Y S, Hong J. et al . Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer.  Anticancer Drugs. 2008;  19 303-307
• 22 Polyzos A, Tsavaris N, Kosmas C. et al . Subsets of patients with advanced gastric cancer responding to second-line chemotherapy with docetaxel-cisplatin.  Anticancer Res. 2006;  26 3749-3753
• 23 Rosati G, Bilancia D, Germano D. et al . Reduced dose intensity of docetaxel plus capecitabine as second-line palliative chemotherapy in patients with metastatic gastric cancer.  Ann Oncol. 2007;  18 Suppl 6 vi128-132
• 24 Schmitz S H, Voliotis D L, Schimke J, Diehl V. Continuous 5-fluorouracil and leucovorin as a second-line therapy for advanced gastric carcinoma.  Oncology. 1994;  51 502-506
• 25 Sencan O, Buyukcelik A, Yalcin B. et al . The symptomatic benefit (the clinical benefit response) from the second-line chemotherapy in patients with advanced gastric adenocarcinoma.  Eur J Cancer Care. 2008;  17 26-32
• 26 Shimada S, Yagi Y, Kuramoto M, Aoki N, Ogawa M. Second-line chemotherapy with combined irinotecan and low-dose cisplatin for patients with metastatic gastric carcinoma resistant to 5-fluorouracil.  Oncol Rep. 2003;  10 687-691
• 27 Stahl M, Muller C, Koster W, Wilke H. Second-line chemotherapy of advanced disseminated gastric cancer after cisplatin, infusional 5-fluorouracil, folinic acid (PLF).  Onkologie. 2005;  28 499-502
• 28 Stathopoulos G P, Rigatos S K, Fountzilas G, Polyzos A, Stathopoulos J G. Paclitaxel and carboplatin in pretreated advanced gastric cancer.  Oncol Rep. 2002;  9 89-92
• 29 Thuss-Patience P C, Kretzschmar A, Deist T. et al . Irinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer.  J Clin Oncol. 2009;  27 Suppl; abstr 4540)
• 30 Van Cutsem E KY, Chung H. et al . Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC).  J Clin Oncol. 2009;  27 Suppl. abstr LBA4509
• 31 Vanhoefer U, Wilke H, Weh H J. et al . Weekly high-dose 5-fluorouracil and folinic acid as salvage treatment in advanced gastric cancer.  Ann Oncol. 1994;  5 850-851
• 32 Zhong H, Zhang Y, Ma S. et al . Docetaxel plus oxaliplatin (DOCOX) as a second-line treatment after failure of fluoropyrimidine and platinum in Chinese patients with advanced gastric cancer.  Anti-cancer Drugs. 2008;  19 1013-1018